Dina Rollman
About Dina Rollman
Independent director of NewLake Capital Partners, Inc. (NLCP) since December 12, 2024; age 52. CEO of StrainBrain (AI-powered cannabis shopping technology), board member of its parent company PowerPlant, and co-founder of KND Group (law and consulting for regulated industries). Previously helped take Green Thumb Industries (OTCQX: GTBIF) public in 2018 and built its Government Affairs, Regulatory Compliance, competitive licensing, and Social Impact functions; co-founded Illinois Women in Cannabis in 2014; earlier partner at Sperling & Slater and founder of Rollman Law Group. Education: B.A. Oberlin College; J.D. Northwestern University School of Law .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| StrainBrain (PowerPlant portfolio) | Chief Executive Officer | Current | Leads AI-driven product recommendation platform for legal cannabis retail |
| PowerPlant | Board Member | Current | Parent of StrainBrain; board service |
| KND Group | Co-Founder | Current | Law and consulting for highly regulated industries (incl. cannabis) |
| Green Thumb Industries (OTCQX: GTBIF) | Executive (Gov’t Affairs, Regulatory Compliance, Licensing, Social Impact) | 2018 onward (public listing in 2018; prior service implied) | Helped take GTI public; created and led key functions in compliance and impact |
| Illinois Women in Cannabis (non-profit) | Co-Founder; President | Since 2014 | State-leading professional networking org with 1,000+ paid members |
| Sperling & Slater | Partner | 2005–2015 | Litigation/commercial law partner |
| Rollman Law Group | Founder | 2015 onward | Founded law practice after Sperling & Slater |
External Roles
| Organization | Public/Private | Role | Notes |
|---|---|---|---|
| PowerPlant | Private | Board Member | Parent of StrainBrain |
| StrainBrain | Private | CEO | AI-powered cannabis shopping tech |
| KND Group | Private | Co-Founder | Regulated industries advisory (incl. cannabis) |
| Illinois Women in Cannabis | Non-profit | Co-Founder/President | 1,000+ paid members; networking organization |
No other public company directorships are disclosed for Ms. Rollman .
Board Governance
- Independence: Board determined Ms. Rollman is independent under OTCQX standards; no family relationships disclosed .
- Board service and attendance: Joined December 12, 2024; consequently did not attend 75% of 2024 board meetings due to late appointment (board held 12 meetings in 2024; committees met Audit 4, Nominating 5, Compensation 4, ESG 4, Investment 3) .
- Committee assignments (effective after the 2025 annual meeting): Audit (Member), Nominating & Corporate Governance (Member), Environmental, Social & Governance (Chair) .
- Board leadership and structure: Independent chair separate from CEO; independent directors hold executive sessions; anti-hedging and anti-pledging policies apply to directors .
| Committee (effective June 5, 2025) | Role |
|---|---|
| Audit | Member |
| Nominating & Corporate Governance | Member |
| Environmental, Social & Governance (ESG) | Chair |
Fixed Compensation
| Component | 2024 Amount/Terms | Notes |
|---|---|---|
| Fees earned (cash) | $2,174 | Pro-rated from Dec 12, 2024 start date |
| Stock awards (RSUs grant-date fair value) | $30,697 | Pro-rated RSU grant for board service |
| Annual director cash retainer | $40,000 | Non-chair directors; paid quarterly |
| Committee chair retainers | Audit $17,500; Compensation $12,500 (rising to $15,000 on 6/5/25); ESG $11,500 (falling to $10,000 on 6/5/25); Nominating $7,500 (rising to $10,000 on 6/5/25); Investment Chair $8,750 (move to single Chair $10,000 on 6/5/25) | |
| Multi-committee member retainer | $10,000 (for members on two or more committees, non-chairs) | Paid quarterly |
| Meeting fees | $1,500 per board meeting from the 11th; $1,500 per committee meeting from the 11th | If meetings exceed 10 per year |
RSU vesting terms for directors: Board RSUs vest on the earlier of the first anniversary of grant or the date of the next annual meeting (June 5, 2025 for 2024 grants), subject to continued service; directors may elect RSUs in lieu of cash (Mr. Kadens did so in 2024) .
Performance Compensation
- NLCP’s non-employee directors do not receive performance-based equity; director RSUs are time-based (service-vesting) with no disclosed performance metrics .
Other Directorships & Interlocks
- Nominator affiliation: Ms. Rollman was nominated by the “West Stockholders” under the Investor Rights Agreement (West Investment Holdings, West CRT Heavy, Gary and Mary West-related entities) who collectively may nominate one director while holding at least 5% of shares; West-related entities collectively held stakes including warrants via NLCP Holdings, LLC as of the proxy .
- No related party transactions involving Ms. Rollman are disclosed; related-party transactions require Audit Committee approval per policy .
Expertise & Qualifications
- Cannabis regulatory and licensing expertise; led government affairs, compliance, licensing application, and social impact functions at GTI; co-founded leading state cannabis industry network (IWiC) .
- Legal background (partner-level experience; J.D. Northwestern) and founder of law/consulting firm for regulated industries .
- Technology/AI exposure via CEO role at StrainBrain (AI product recommendation platform) .
Equity Ownership
| Item | Detail |
|---|---|
| Beneficial ownership (as of April 10, 2025) | 1,563 shares; less than 1% of outstanding |
| RSUs outstanding (as of 12/31/24) | 1,563 RSUs (director grant) |
| RSU vesting | Director RSUs vest 100% on the earlier of first anniversary or June 5, 2025 annual meeting, subject to continued service |
| Beneficial table footnote | Footnote indicates 3,117 RSUs scheduled to vest on June 5, 2025, subject to continued service |
| Pledged shares | None; company policy prohibits pledging; and no shares beneficially owned by directors/officers have been pledged |
| Conversion restriction | Vested director RSUs cannot be converted to common stock until the director separates from the Company |
Governance Assessment
- Strengths:
- Independent status affirmed; no family relationships; anti-hedging/anti-pledging policies enhance alignment .
- Brings specialized cannabis regulatory and compliance expertise, valuable for NLCP’s cannabis-focused REIT model .
- Assigned to Audit and Nominating & Governance and designated Chair of ESG effective June 5, 2025, signaling trust in oversight roles .
- Watch items:
- Attendance below 75% in 2024 due to late-December appointment (non-systemic, but will monitor 2025 attendance once a full year elapses) .
- Nominated by significant shareholder group (West Stockholders) under Investor Rights Agreement—board determined independence, but investors should monitor potential alignment with nominating stockholder interests vs. broader shareholder base .
- Compensation/ownership alignment:
- 2024 compensation heavily equity-oriented via RSUs (service-vesting) with minimal cash due to pro-rating; director RSUs deferred until separation, promoting longer-term alignment; no pledging permitted .
- Related-party/conflicts:
- No related-party transactions disclosed; Related Party Transaction Policy requires Audit Committee approval for any such items .
- Ms. Rollman’s executive role in cannabis technology (StrainBrain) creates industry adjacency; no disclosed transactions with NLCP or tenants; continue monitoring future disclosures .
RED FLAGS (to monitor): Late-year appointment led to sub-75% 2024 attendance; ensure full-year attendance in 2025 meets guidelines . Nominator linkage to West Stockholders (large holders with board nomination rights); maintain vigilance for potential conflicts though independence affirmed .